Talaria Asset Management Pty Ltd Has $40.17 Million Position in Medtronic PLC $MDT

Talaria Asset Management Pty Ltd trimmed its position in shares of Medtronic PLC (NYSE:MDT) by 21.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 447,000 shares of the medical technology company’s stock after selling 120,600 shares during the quarter. Medtronic accounts for about 13.4% of Talaria Asset Management Pty Ltd’s holdings, making the stock its 6th largest holding. Talaria Asset Management Pty Ltd’s holdings in Medtronic were worth $40,167,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in MDT. Brighton Jones LLC increased its position in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Medtronic during the 4th quarter valued at $13,546,000. Beacon Pointe Advisors LLC raised its stake in Medtronic by 21.4% in the 4th quarter. Beacon Pointe Advisors LLC now owns 20,356 shares of the medical technology company’s stock worth $1,626,000 after acquiring an additional 3,589 shares during the last quarter. Optiver Holding B.V. purchased a new position in shares of Medtronic during the 4th quarter valued at about $31,000. Finally, The Manufacturers Life Insurance Company grew its position in shares of Medtronic by 33.0% during the 4th quarter. The Manufacturers Life Insurance Company now owns 4,325,726 shares of the medical technology company’s stock valued at $345,538,000 after acquiring an additional 1,073,545 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Medtronic Stock Down 0.7%

Shares of MDT stock opened at $92.02 on Tuesday. The company has a market capitalization of $117.95 billion, a price-to-earnings ratio of 25.35, a P/E/G ratio of 2.35 and a beta of 0.80. The company has a quick ratio of 1.42, a current ratio of 1.85 and a debt-to-equity ratio of 0.53. The firm has a fifty day moving average of $89.81 and a 200-day moving average of $88.00. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $96.25.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.56%. The business’s revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is 78.24%.

Insider Transactions at Medtronic

In other Medtronic news, Director William R. Jellison purchased 2,500 shares of the firm’s stock in a transaction on Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the completion of the purchase, the director owned 5,000 shares of the company’s stock, valued at $461,850. The trade was a 100.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MDT. BTIG Research reissued a “neutral” rating on shares of Medtronic in a research report on Friday, July 11th. Mizuho lifted their price objective on Medtronic from $98.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. William Blair raised shares of Medtronic to a “hold” rating in a research report on Friday, July 11th. Finally, Sanford C. Bernstein boosted their target price on Medtronic from $97.00 to $98.00 and gave the stock an “outperform” rating in a report on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $101.15.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.